CHICAGO (Reuters) - Dimebon, Medivation Inc’s promising experimental Alzheimer’s drug, significantly raised levels of a toxic protein in the brains of mice, yet has been shown to delay thinking problems in human dementia patients, U.S. researchers said on Wednesday.
